8-K: Charles River Labs Reports Q3 2025 Results, Updates Guidance

Charles River Laboratories International, Inc. announced third-quarter 2025 financial results, reporting $1.00 billion in revenue and updating its full-year 2025 guidance.

Summary

• Third-quarter 2025 revenue was $1.00 billion, a 0.5% decrease from $1.01 billion in the third quarter of 2024, with an organic revenue decline of 1.6%.
• GAAP earnings per diluted share (EPS) for Q3 2025 decreased to $1.10 from $1.33 in Q3 2024.
• Non-GAAP EPS for Q3 2025 decreased to $2.43 from $2.59 in Q3 2024.
• GAAP net income available to common shareholders was $54.4 million, down from $68.7 million in Q3 2024.
• Non-GAAP net income was $120.3 million, a 10.0% decrease from $133.7 million in Q3 2024.
• The Research Models and Services (RMS) segment revenue increased by 7.9% to $213.5 million, with organic growth of 6.5%.
• The Discovery and Safety Assessment (DSA) segment revenue decreased by 2.3% to $600.7 million, with an organic decline of 3.1%.
• The Manufacturing Solutions (Manufacturing) segment revenue decreased by 3.1% to $190.7 million, with an organic decline of 5.1%.
• The company updated its 2025 financial guidance, narrowing the full-year outlook for revenue and non-GAAP EPS to the middle and upper ends of the previous ranges, respectively, reflecting Q3 performance that modestly exceeded prior outlook.

Sentiment

Score: 6

Explanation: While revenue and non-GAAP EPS declined year-over-year, the company's Q3 performance modestly exceeded its own prior outlook, leading to a narrowed and slightly improved full-year guidance range. Strong performance in the RMS segment and improved GAAP operating margin are positives, but organic revenue declines in DSA and Manufacturing, along with a significant loss from strategic investments, temper the overall sentiment. Management's cautious optimism about industry recovery is noted.

Positives

• GAAP operating margin increased to 13.3% in Q3 2025 from 11.6% in Q3 2024, primarily driven by lower costs associated with restructuring initiatives.
• The Research Models and Services (RMS) segment achieved strong organic revenue growth of 6.5%, primarily due to higher revenue for large research model products.
• RMS segment GAAP operating margin increased to 16.2% from 13.9%, and non-GAAP operating margin increased to 25.0% from 21.0%, driven by favorable revenue mix and cost savings.
• Manufacturing segment GAAP operating margin increased to 20.9% from 20.4%, benefiting from lower acquisition-related amortization adjustments and restructuring cost savings.
• The updated 2025 guidance reflects third-quarter financial performance that modestly exceeded the company's prior outlook, leading to a narrowed and improved full-year forecast.
• Lower interest expense contributed to non-GAAP net income.
• A reduction in diluted shares outstanding from stock repurchases positively impacted non-GAAP EPS.

Negatives

• Total reported revenue decreased by 0.5% to $1.00 billion, with an organic decline of 1.6% in Q3 2025.
• GAAP net income decreased to $54.4 million from $68.7 million, and GAAP EPS decreased to $1.10 from $1.33.
• Non-GAAP net income decreased by 10.0% to $120.3 million, and non-GAAP EPS decreased by 6.2% to $2.43.
• The decrease in GAAP net income and EPS was primarily driven by a $0.33 per share loss from certain venture capital and other strategic investments in Q3 2025, compared to a $0.03 gain last year.
• The non-GAAP net income and EPS decreases were primarily driven by lower revenue and a higher tax rate.
• The Discovery and Safety Assessment (DSA) segment experienced an organic revenue decrease of 3.1%, mainly due to lower sales volume for both discovery and regulated safety assessment services.
• DSA segment non-GAAP operating margin decreased to 25.4% from 27.4%, primarily as a result of lower revenue.
• The Manufacturing Solutions segment saw an organic revenue decrease of 5.1%, driven by lower revenue in the CDMO and Biologics Testing businesses.
• Manufacturing segment non-GAAP operating margin decreased to 26.7% from 28.7%, primarily due to lower revenue in the CDMO business.
• Management noted ongoing uncertainty in the healthcare sector.

Risks

• Uncertainty in the healthcare sector, which may impact sustained business improvement.
• The timing of the resumption of Cambodia non-human primate (NHP) imports into the U.S.
• The ability to manage supply impact and potential study delays in the DSA segment attributable to NHP supply constraints.
• Changes and uncertainties in the global economy and financial markets.
• The ability to successfully integrate businesses acquired by the company.
• Negative trends in research and development spending, outsourced services, or other cost reduction actions by clients.
• The ability to convert backlog to revenue.
• Risks related to special interest groups, contaminations, industry trends, and new displacement technologies.
• Compliance with USDA and FDA regulations and potential changes in law.
• Continued availability of products and supplies.
• Loss of key personnel.
• Interest rate and foreign currency exchange rate fluctuations.
• Changes in tax regulation and laws, and changes in generally accepted accounting principles.
• Disruptions in the global economy caused by geopolitical conflicts.
• Changes in business, political, or economic conditions due to the threat of future terrorist activity.
• U.S. government investigations into the NHP supply chain related to the DSA segment.

Future Outlook

The company updated its 2025 financial guidance, narrowing the full-year outlook for revenue and non-GAAP earnings per share to the middle and upper ends of the previous ranges, respectively, primarily reflecting the third-quarter financial performance which modestly exceeded the company's prior outlook. Management believes positive signals are beginning to emerge, indicating a potential path towards industry recovery, but cautions that sustained improvement will take time due to ongoing uncertainty in the healthcare sector. The company remains focused on its strategy to differentiate through science and innovative solutions, implement initiatives to unlock value, and gain additional share in client drug development and manufacturing programs.

Management Comments

• "Our solid third-quarter financial results demonstrate that the demand for our extensive portfolio of early-stage research and manufacturing products and services remains stable."
• "We believe that positive signals are beginning to emerge which indicate that the industry may be on a path towards recovery; however, sustained improvement in our business will take time. There is still some uncertainty in the healthcare sector, so we are remaining cautious at this time."
• "In this environment, we believe it is critical to remain intently focused on our strategy to further differentiate ourselves from the competition through our science and our innovative solutions, implement additional initiatives to unlock value, and gain additional share of our clients drug development and manufacturing programs. This focus on our strategy and our science positions us extremely well to lead the industry through advances in drug development."

Industry Context

The company acknowledges a prevailing "uncertainty in the healthcare sector" but also notes "positive signals are beginning to emerge" suggesting a potential industry recovery. This indicates a cautious outlook on the broader market for drug discovery and development services, which has faced headwinds. The company's strategic focus on scientific differentiation and innovative solutions highlights a competitive landscape where capturing market share is crucial amidst evolving client needs and funding dynamics.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Corporate Governance

Legal Proceedings

• U.S. government investigations into the non-human primate (NHP) supply chain related to the Discovery and Safety Assessment (DSA) segment.
• Reductions to the previous $27 million inventory charge incurred during fiscal 2024, to write down inventory associated with the Cambodia-sourced NHP matter from February 16, 2023, as a result of the cases being closed during fiscal 2025.

Stakeholder Impact

• Shareholders are impacted by decreased GAAP and non-GAAP EPS, but also by stock repurchases and an improved outlook for 2025 guidance. There is potential for long-term value creation through strategic focus.
• Employees are impacted by restructuring initiatives and associated cost savings.
• Customers will continue to receive essential products and services for drug development, with a focus on innovative solutions and efforts to gain additional share of their programs.
• Suppliers, particularly those in the non-human primate supply chain, face scrutiny and potential disruptions, which could affect the DSA segment.

Next Steps

• A live webcast is scheduled for Wednesday, November 5th, at 9:00 a.m. ET to discuss matters relating to this press release.
• The company intends to remain intently focused on its strategy to further differentiate itself through science and innovative solutions.
• The company plans to implement additional initiatives to unlock value and gain additional share of clients' drug development and manufacturing programs.

Key Dates

Recommendation

The company's Q3 results present a mixed picture with overall revenue and non-GAAP EPS declines, yet also show some positive operational improvements and a slightly better-than-expected quarter, leading to an improved full-year outlook. The ongoing non-human primate supply chain issues and a significant loss from strategic investments are notable headwinds. While management expresses cautious optimism for industry recovery, the current environment still presents uncertainties. The stock repurchases are a positive for shareholders. Given these mixed signals and the prevailing industry uncertainty, a 'hold' recommendation is appropriate, suggesting investors await clearer signs of sustained recovery and resolution of supply chain issues before making significant changes to their position.

Keywords

Charles River Laboratories, CRL, Q3 2025 earnings, financial results, revenue, EPS, guidance, pharmaceutical services, biotechnology services, drug development, research models, safety assessment, manufacturing solutions, non-human primate supply chain, corporate governance, SEC filing